Sarah J. Fink

Sarah J. Fink

Auto-generated profile, based on publicly available information

Sarah J. Fink

Takeda Pharmaceuticals, 125 Binney Street, Cambridge, Massachusetts 02142, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AFAndrew C. Flick
Andrew C. Flick
CLCarolyn A. Leverett
Carolyn A. Leverett
HDHong X. Ding
Hong X. Ding
EMEmma L. McInturff
Emma L. McInturff
SFSarah J. Fink
Sarah J. Fink
COChristopher J. O’dOnnell
Christopher J. O’dOnnell

15 March 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SFScott P. France
Scott P. France
ELErick A. Lindsey
Erick A. Lindsey
EMEmma L. McInturff
Emma L. McInturff
SBSimon Berritt
Simon Berritt
DCDaniel W. Carney
Daniel W. Carney
RWRebecca B. Watson
Rebecca B. Watson

1 August 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EMEmma L. McInturff
Emma L. McInturff
SFScott P. France
Scott P. France
CLCarolyn A. Leverett
Carolyn A. Leverett
AFAndrew C. Flick
Andrew C. Flick
ELErick A. Lindsey
Erick A. Lindsey
COChristopher J. O’donnell
Christopher J. O’donnell

3 February 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SFScott P. France
Scott P. France
ELErick A. Lindsey
Erick A. Lindsey
EMEmma L. McInturff
Emma L. McInturff
SBSimon Berritt
Simon Berritt
JDJacob DeForest
Jacob DeForest
ZZZhiyao Zhou
Zhiyao Zhou

6 November 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JYJian-Ping Yang
Jian-Ping Yang
RTRachel Toughiri
Rachel Toughiri
AGAnshu P Gounder
Anshu P Gounder
DSDan Scheibe
Dan Scheibe
MPMatt Petrus
Matt Petrus
SHShane R Horman
Shane R Horman
Induction of fetal hemoglobin (HbF) has been shown to be a viable therapeutic approach to treating sickle cell disease and potentially other β-hemoglobinopathies. To identify targets and target-modulating small molecules that enhance HbF expression, we engineered a human umbilical-derived erythroid progenitor reporter cell line (HUDEP2_HBG1_HiBiT) by genetically tagging a HiBiT peptide to the carboxyl (C)-terminus of the endogenous HBG1 gene locus, which codes for γ-globin protein, a component of HbF. Employing this reporter cell line, we performed a chemogenomic screen of approximately 5000 compounds annotated with known targets or mechanisms that have achieved clinical stage or approval by the US Food and Drug Administration (FDA). Among them, 10 compounds were confirmed for their ability to induce HbF in the HUDEP2 cell line. These include several known HbF inducers, such as pomalidomide, lenalidomide, decitabine, idoxuridine, and azacytidine, which validate the translational nature of this screening platform. We identified avadomide, autophinib, triciribine, and R574 as novel HbF inducers from these screens. We orthogonally confirmed HbF induction activities of the top hits in both parental HUDEP2 cells as well as in human primary CD34+ hematopoietic stem and progenitor cells (HSPCs). Further, we demonstrated that pomalidomide and avadomide, but not idoxuridine, induced HbF expression through downregulation of several transcriptional repressors such as BCL11A, ZBTB7A, and IKZF1. These studies demonstrate a robust phenotypic screening workflow that can be applied to large-scale small molecule profiling campaigns for the discovery of targets and pathways, as well as novel therapeutics for sickle cell disease and other β-hemoglobinopathies.

15 August 2023 in Organic Process Research & Development
Verified
Journal Article
Open access
MFM. Jonathan Fray
M. Jonathan Fray
SFSarah J. Fink
Sarah J. Fink
XHXiao Han
Xiao Han
NPNikolaos Papaioannou
Nikolaos Papaioannou
ARAndreas Rennhack
Andreas Rennhack
LZLianhua Zou
Lianhua Zou